Filing Details
- Accession Number:
- 0001209191-21-066168
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-22 17:45:38
- Reporting Period:
- 2021-11-18
- Accepted Time:
- 2021-11-22 17:45:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 651311552 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1586893 | Scott J Wolchko | C/O Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego CA 92131 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-11-18 | 20,000 | $2.70 | 413,793 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-18 | 20,000 | $54.27 | 393,793 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-11-19 | 86,475 | $0.00 | 480,268 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-11-18 | 20,000 | $0.00 | 20,000 | $2.70 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 79,446 | 2026-01-11 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.
- These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.
- This option is fully vested.
Billionaire Hedge Funds
